CD38 and Cognitive impairment: In an exploratory investigation into concepts that influenced treatment choices for patients with MM and that analyzed patients (N=30) receiving proteasome inhibitors (66.7%), immunomodulatory drugs (56.7%), chemotherapy (30%; bendamustine, cisplatin, cyclophosphamide, doxorubicin, etoposide, and melphalan), steroids (70%), and CD38 inhibitors (16.7%), peripheral neuropathy (90%) was the most reported symptom attributed to treatment, followed by diarrhea (83%) and cognitive impairment (83%) [28].